Every 10-Q that Heartbeam, Inc. (BEAT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BEAT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BEAT filings page.
HeartBeam, Inc. reported no revenue for the quarter and six months ended June 30, 2026 and continues to operate at a loss while developing its ambulatory cardiac monitoring platform. Net loss was $5.0 million for the quarter and $9.7 million for the first half of 2026.
Cash and cash equivalents were $8.7 million as of June 30, 2026, up from $4.4 million at year-end, primarily from an underwritten equity offering that generated $11.5 million in gross proceeds (about $10.3 million net) plus at-the-market sales. Operating cash outflow was $7.0 million in the first half.
The company discloses that existing liquidity is insufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern. It received FDA clearances in December 2024 and December 2025 for its 3D ECG telehealth products, is running pilot and ALIGN-ACS studies, and is pursuing a shift toward licensing its 3D ECG signal technology and limited commercial launches. During the quarter HeartBeam also recorded CEO and director departures and received a Nasdaq minimum bid-price deficiency notice with a compliance period through December 29, 2026.
HeartBeam, Inc. reported another quarter of losses with no revenue and highlighted serious liquidity concerns. For the three months ended March 31, 2026, the company generated no revenue and recorded a net loss of $4.7 million, narrower than the $5.5 million loss a year earlier. Operating expenses were $4.7 million, with selling, general and administrative costs rising 17% and research and development falling 32% as product development and consulting spending declined.
Cash and cash equivalents were $2.0 million as of March 31, 2026, and management stated this is insufficient to fund operations for the next twelve months, raising “substantial doubt” about the company’s ability to continue as a going concern. Subsequent to quarter-end, HeartBeam completed an underwritten offering of 14,375,000 shares of common stock for gross proceeds of approximately $11.5 million. The company remains pre-revenue despite FDA clearances for its 3D ECG telehealth system and is beginning a limited commercial launch and multiple pilot studies, while expecting no material commercial revenue in 2026.
HeartBeam, Inc. reported third‑quarter results showing a net loss of $5.3 million and reiterated substantial doubt about its ability to continue as a going concern based on current cash resources. Cash and cash equivalents were $1.856 million, with cash used in operations of $11.1 million for the first nine months.
Operating expenses were $5.29 million in the quarter, as R&D rose while G&A declined. Year‑to‑date, the company raised $10.25 million net in a February public offering and $0.49 million via its ATM program. The ATM capacity remaining was approximately $15.5 million, potentially subject to baby shelf limitations.
HeartBeam received FDA clearance in December 2024 for its initial ambulatory ECG system and filed a 510(k) in January 2025 for its 12‑lead synthesis software. It launched an early access program for user feedback and highlighted AI study data supporting arrhythmia classification. Common shares outstanding were 34,340,727 as of September 30, 2025; shares outstanding were 34,443,563 as of November 11, 2025.
HeartBeam, Inc. reported total assets of $5.98 million and combined cash and short-term investments of approximately $5.1 million as of June 30, 2025, with cash and equivalents of $3.26 million. The company recorded a net loss of $4.97 million for the quarter and $10.46 million for the six months ended June 30, 2025, and had an accumulated deficit of $66.73 million. Stockholders' equity was $4.18 million and shares outstanding increased to 34.02 million by June 30, 2025.
R&D expense rose year-to-date as product development and headcount increased while G&A declined. The company completed a February public offering that produced approximately $11.5 million in gross proceeds (about $10.3 million net) and issued shares under an ATM, leaving roughly $15.6 million available under that program. The HeartBeam System received FDA clearance on December 13, 2024; the company filed a 510(k) for its 12-lead synthesis software in January 2025, and its VALID-ECG pivotal study showed 93.4% diagnostic agreement. Management discloses substantial doubt about the company’s ability to continue as a going concern absent additional financing.